# US 2016/0250321 A1 · NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENT/ADJUVANT

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250321 A1
- Document ID: US20160250321A1
- Status: Published application
- Kind: A1
- Application number: 14/954,363
- Filed: 2015-11-30
- Published: 2016-09-01
- Earliest claimed: 2008-01-31
- Assignees: CureVac AG
- Applicants: CureVac AG
- Inventors: Thomas KRAMPS; Söhnke VOSS; Jochen PROBST; Ingmar HOERR
- Web page: https://patentgrep.com/patent/US20160250321A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 17/14: for baldness or alopecia
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/04: for myasthenia gravis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/06: for tuberculosis
- A61P 31/08: for leprosy
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- A61P 31/20: for DNA viruses
- A61P 31/22: for herpes viruses
- A61P 33/00: Antiparasitic agents
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 33/04: Amoebicides
- A61P 33/06: Antimalarials
- A61P 33/10: Anthelmintics
- A61P 33/12: Schistosomicides
- A61P 33/14: Ectoparasiticides, e.g. scabicides
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C12N 15/117: Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/572: {cytotoxic response}
- C12N 2310/17: Immunomodulatory nucleic acids
- C12N 2310/314: Phosphoramidates
- C12N 2310/315: Phosphorothioates
- C12N 2320/31: Combination therapy
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to nucleic acids of the general formula (I): (NuGlXmGnNv)a and derivatives thereof as an immunostimulating agent/adjuvant and to compositions containing same, optionally comprising an additional adjuvant. The present invention furthermore relates to a pharmaceutical composition or to a vaccine, each containing nucleic acids of formula (I) above and/or derivatives thereof as an immunostimulating agent, and optionally at least one additional pharmaceutically active component, e.g. an antigenic agent. The present invention relates likewise to the use of the pharmaceutical composition or of the vaccine for the treatment of cancer diseases, infectious diseases, allergies and autoimmune diseases etc. Likewise, the present invention includes the use of nucleic acids of the general formula (I): (NuGlXmGnNv)a and/or derivatives thereof for the preparation of a pharmaceutical composition for the treatment of such diseases.

## Claims

### Claim at position 1

1-25. (canceled)

### Claim 26

An isolated nucleic acid molecule comprising at least 100 contagious nucleotides of SEQ ID NO: 114-119 or the DNA coding sequence thereof, provided that:
the guanosine (guanine), the uridine (uracil), the adenosine (adenine), the thymidine (thymine), or the cytidine (cytosine) positions of the nucleotide (nucleoside) sequence of the nucleic acid molecule may be substituted with an analogue of nucleotides (nucleosides) selected from 1-methyl-adenosine (adenine), 2-methyl-adenosine (adenine), 2-methylthio-N6-isopentenyl-adenosine (adenine), N6-methyl-adenosine (adenine), N6-isopentenyl-adenosine (adenine), 2-thio-cytidine (cytosine), 3-methyl-cytidine (cytosine), 4-acetyl-cytidine (cytosine), 2,6-diaminopurine, 1-methyl-guanosine (guanine), 2-methyl-guanosine (guanine), 2,2-dimethyl-guanosine (guanine), 7-methyl-guanosine (guanine), inosine, 1-methyl-inosine, dihydro-uridine (uracil), 4-thio-uridine (uracil), 5-carboxymethylaminomethyl-2-thio-uridine (uracil), 5-(carboxyhydroxylmethyl)-uridine (uracil), 5-fluoro-uridine (uracil), 5-bromo-uridine (uracil), 5-carboxymethylaminomethyl-uridine (uracil), 5-methyl-2-thio-uridine (uracil), N-uridine (uracil)-5-oxyacetic acid methyl ester, 5-methylaminomethyl-uridine (uracil), 5-methoxyaminomethyl-2-thio-uridine (uracil), 5′-methoxycarbonylmethyl-uridine (uracil), 5-methoxy-uridine (uracil), uridine (uracil)-5-oxyacetic acid methyl ester, uridine (uracil)-5-oxyacetic acid (v), queosine, beta-D-mannosyl-queosine, wybutoxosine, and inosine;
phosphate moieties may be substituted with phosphoramidates, phosphorothioates, peptide nucleotides, or methylphosphonates; and
ribose components may be substituted with deoxyribose.

### Claim 27 (depends on 26)

The isolated nucleic acid molecule of claim 26, comprising at least 150 contagious nucleotides of SEQ ID NO: 114-119.

### Claim 28 (depends on 27)

The isolated nucleic acid molecule of claim 27, comprising at least 200 contagious nucleotides of SEQ ID NO: 114-119.

### Claim 29 (depends on 26)

The isolated nucleic acid molecule of claim 26, comprising at least 200 contagious nucleotides of SEQ ID NO: 114-116.

### Claim 30 (depends on 29)

The isolated nucleic acid molecule of claim 29, comprising at least 200 contagious nucleotides of SEQ ID NO: 114.

### Claim 31 (depends on 30)

The isolated nucleic acid molecule of claim 30, comprising the sequence of SEQ ID NO: 114.

### Claim 32 (depends on 26)

The isolated nucleic acid molecule of claim 26, comprising at least 200 contagious nucleotides of SEQ ID NO: 117-119.

### Claim 33 (depends on 32)

The isolated nucleic acid molecule of claim 32, comprising at least 200 contagious nucleotides of SEQ ID NO: 117.

### Claim 34 (depends on 33)

The isolated nucleic acid molecule of claim 33, comprising the sequence of SEQ ID NO: 117.

### Claim 35 (depends on 26)

The isolated nucleic acid molecule of claim 26, wherein the nucleic acid molecule is RNA.

### Claim 36 (depends on 26)

The isolated nucleic acid molecule of claim 26, wherein the nucleic acid molecule is single-stranded.

### Claim 37 (depends on 26)

The isolated nucleic acid molecule of claim 26, wherein the nucleic acid molecule is double-stranded or partially double-stranded.

### Claim 38 (depends on 26)

The isolated nucleic acid molecule of claim 26, wherein the nucleic acid molecule is linear.

### Claim 39 (depends on 26)

The isolated nucleic acid molecule of claim 26, wherein the nucleic acid molecule is complexed with a lipid, polycationic compound, or polycationic polypeptide.

### Claim 40 (depends on 26)

The isolated nucleic acid molecule of claim 26, wherein the nucleic acid molecule does not comprise a nucleoside analogue.

### Claim 41 (depends on 26)

The isolated nucleic acid molecule of claim 26, comprising at least 200 contagious nucleotides of SEQ ID NO: 114-119 or the DNA coding sequence thereof, provided that:
the guanosine (guanine), the uridine (uracil), the adenosine (adenine), the thymidine (thymine), or the cytidine (cytosine) positions of the nucleotide (nucleoside) sequence of the nucleic acid molecule may be substituted with an analogue of nucleotides (nucleosides) selected from 1-methyl-adenosine (adenine), 2-methyl-adenosine (adenine), 2-methylthio-N6-isopentenyl-adenosine (adenine), N6-methyl-adenosine (adenine), N6-isopentenyl-adenosine (adenine), 2-thio-cytidine (cytosine), 3-methyl-cytidine (cytosine), 4-acetyl-cytidine (cytosine), 2,6-diaminopurine, 1-methyl-guanosine (guanine), 2-methyl-guanosine (guanine), 2,2-dimethyl-guanosine (guanine), 7-methyl-guanosine (guanine), inosine, 1-methyl-inosine, dihydro-uridine (uracil), 4-thio-uridine (uracil), 5-carboxymethylaminomethyl-2-thio-uridine (uracil), 5-(carboxyhydroxylmethyl)-uridine (uracil), 5-fluoro-uridine (uracil), 5-bromo-uridine (uracil), 5-carboxymethylaminomethyl-uridine (uracil), 5-methyl-2-thio-uridine (uracil), N-uridine (uracil)-5-oxyacetic acid methyl ester, 5-methylaminomethyl-uridine (uracil), 5-methoxyaminomethyl-2-thio-uridine (uracil), 5′-methoxycarbonylmethyl-uridine (uracil), 5-methoxy-uridine (uracil), uridine (uracil)-5-oxyacetic acid methyl ester, uridine (uracil)-5-oxyacetic acid (v), queosine, beta-D-mannosyl-queosine, wybutoxosine, and inosine;
phosphate moieties may be substituted with phosphoramidates, phosphorothioates, peptide nucleotides, or methylphosphonates; and
ribose components may be substituted with deoxyribose.

### Claim 42 (depends on 41)

The isolated nucleic acid molecule of claim 41, wherein the nucleic acid molecules is RNA.

### Claim 43 (depends on 41)

The isolated nucleic acid molecule of claim 41, wherein the nucleic acid molecule does not comprise a nucleoside analogue.

### Claim 44 (depends on 26)

A pharmaceutical composition comprising the nucleic acid molecule according to claim 26 and a pharmaceutically acceptable carrier.

### Claim 45 (depends on 44)

The pharmaceutical composition of claim 44, further comprising an adjuvant.

### Claim 46 (depends on 44)

The pharmaceutical composition of claim 44, further comprising an antigen.

### Claim 47 (depends on 44)

The pharmaceutical composition of claim 44, wherein the antigen is a RNA encoding polypeptide antigen.

### Claim 48 (depends on 44)

The pharmaceutical composition of claim 44, wherein the antigen is a polypeptide antigen.
